Opening Hours: Sun - Thur 09:00 - 17:00

Fatroxim 200 & 550 mg) 

Active Ingredient

Fatroxim 200 mg contains Rifaximin 200

Fatroxim 550 mg contains Rifaximin 550



Fatroxim 200 & 550 mg is indicated in treatment of 

1. Travelers’ Diarrhea

2. hepatic encephalopathy

3. Irritable Bowel Syndrome with Diarrhea

Pharmacotherabiotic Group

antibacterial drug

Market Name

Fatroxim 200 mg

Fatroxim 550 mg

Dosage Form

Fatroxim is Film Coated Tablets dosage form


To reduce the development of drug-resistant bacteria and maintain the effectiveness of FATROXIM and other antibacterial drugs, FATROXIM when used to treat infection should be used only to treat or prevent infections that are proven or
strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

1. Travelers’ Diarrhea
FATROXIM is indicated for the treatment of travelers’ diarrhea (TD) caused by non-invasive strains of Escherichia coli in adults and pediatric patients 12 years of age and older.
Limitations of Use
FATROXIM should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli

2. Hepatic Encephalopathy
  is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.
In the trials of FATROXIM for HE, 91% of the patients were using lactulose concomitantly. Differences in the treatment effect of those patients not using lactulose concomitantly could not be assessed.
Rifaximin  has not been studied in patients with MELD (Model for End-Stage Liver Disease) scores >25, and only 8.6% of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction

3. Irritable Bowel Syndrome with Diarrhea

FATROXIM is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults


 is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in FATROXIM. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis .

Pregnancy & Lactation

There are no available data on Rifaximin  use in pregnant or breast feeding  women to inform any drug associated risks

Mechanism of Action

FATROXIM has Rifaximin which is an antibacterial drug of the rifamycin class that irreversibly binds the beta sub-unit of the bacterial enzyme DNA-dependent RNA polymerase and consequently inhibits bacterial RNA synthesis.

Rifaximin has a broad antimicrobial spectrum against most of the Gram-positive and negative, aerobic and anaerobic bacteria, including ammonia producing species. Rifaximin may inhibit the division of urea-deaminating bacteria, thereby reducing the production of ammonia and other compounds that are believed to be important to the pathogenesis of hepatic encephalopathy


Ahead toward more

Contact us

52 AlMoltaqa AlArabi